CYTK plans FDA submission for aficamten in non-obstructive HCM
CYTK says aficamten showed robust efficacy and manageable safety in non-obstructive HCM, with an FDA submission planned.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.